Table 1.
Fasting and postmeal glycemic responses to treatment at Week 14
| Parameter | Placebo | MK-0941 dose (mg t.i.d. a.c.) |
|||
|---|---|---|---|---|---|
| 10 | 20 | 30 | 40 | ||
| n | 111 to 114 | 112 to 118 | 113 to 117 | 113 to 117 | 113 to 118 |
| A1C (%) | |||||
| Change from baseline | −0.1 (−0.3 to 0.1) | −0.6 (−0.8 to −0.4) | −0.7 (−0.9 to −0.5) | −0.9 (−1.1 to −0.7) | −0.8 (−1.0 to −0.6) |
| Change from placebo | — | −0.5 (−0.8 to −0.2)* | −0.6 (−0.9 to −0.4)* | −0.8 (−1.1 to −0.5)* | −0.8 (−1.0 to −0.5)* |
| FPG (mg/dL) | |||||
| Change from baseline | −11.8 (−21.4 to −2.1) | −10.0 (−19.9 to 0.0) | −1.5 (−10.9 to 7.9) | −21.1 (−30.9 to −11.2) | −5.0 (−14.9 to 4.8) |
| Change from placebo | — | 1.8 (−11.6 to 15.2) | 10.3 (−2.7 to 23.2) | −9.3 (−22.6 to 4.0) | 6.7 (−6.6 to 20.0) |
| 2-h PMG (mg/dL) | |||||
| Change from baseline | −2.4 (−16.0 to 11.2) | −39.0 (−52.9 to −25.1) | −29.2 (−42.5 to −15.9) | −37.4 (−51.2 to −23.6) | −39.3 (−53.1 to −25.5) |
| Change from placebo | — | −36.6 (−55.6 to −17.5)* | −26.7 (−45.4 to −8.1)** | −35.0 (−54.0 to −16.0)* | −36.9 (−55.9 to −17.9)* |
Change from baseline or change from placebo data are expressed as LS mean change (95% CI).
*P ≤ 0.001 for the between-group difference relative to placebo.
**P ≤ 0.05 for the between-group difference relative to placebo.